Loading…

The origin of fibrin breakdown products and the interpretation of their appearance in the circulation

It has been shown that the incubation of human plasma with urokinase at a concentration sufficient to cause rapid lysis of the clots formed on the addition of thrombin does not give rise to the production of measurable concentrations of non-clottable fibrinogen breakdown products. Also, breakdown pr...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical pathology 1972-03, Vol.25 (3), p.185-190
Main Authors: Gallimore, M. J., Tyler, H. M., Shaw, J. T. B.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-b476t-9a7d315fff21f594029ac75b738d0a523df96065308dc59a5c980f312bf10cb93
cites cdi_FETCH-LOGICAL-b476t-9a7d315fff21f594029ac75b738d0a523df96065308dc59a5c980f312bf10cb93
container_end_page 190
container_issue 3
container_start_page 185
container_title Journal of clinical pathology
container_volume 25
creator Gallimore, M. J.
Tyler, H. M.
Shaw, J. T. B.
description It has been shown that the incubation of human plasma with urokinase at a concentration sufficient to cause rapid lysis of the clots formed on the addition of thrombin does not give rise to the production of measurable concentrations of non-clottable fibrinogen breakdown products. Also, breakdown products could not be detected in the course of experiments in vivo when urokinase was administered to monkeys and only in very low concentrations when a fibrinolytic state was induced by exercise in three healthy human volunteers. In contrast, high concentrations of breakdown products were found after thrombin infusion into monkeys. It is concluded that circulating fibrinogen is not readily broken down into non-clottable products by the fibrinolytic enzymes, and that normal animals and healthy human subjects do not have substantial deposits of fibrin that are available for breakdown during a fibrinolytic episode. The presence of breakdown products in the circulation is therefore likely to be indicative of the fibrinolytic response to an initial coagulation event.
doi_str_mv 10.1136/jcp.25.3.185
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_477259</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>81423895</sourcerecordid><originalsourceid>FETCH-LOGICAL-b476t-9a7d315fff21f594029ac75b738d0a523df96065308dc59a5c980f312bf10cb93</originalsourceid><addsrcrecordid>eNp90cmPFCEUB2BiNGM7evNqUomJXqyWneIwB9MuY9LRy6iJF0JRMENPNZRAufz30ks66sEThPc9eOQHwGMElwgR_nJjpiVmS7JEHbsDFogK3FJE-V2wgBCjVgrK74MHOW8gREQgcgbOKMdYSrYA9urGNjH5ax-a6Brn-1R3fbL6dog_QjOlOMym5EaHoSnV-lBsmpItuvi476mnPjV6mqxOOpgd2Uvjk5nHPXsI7jk9ZvvouJ6DT2_fXK0u2_XHd-9Xr9ZtTwUvrdRiIIg55zByTFKIpTaC9YJ0A9QMk8FJDjkjsBsMk5oZ2UFHEO4dgqaX5BxcHO6d5n5rB2NDSXpUU_JbnX6pqL36uxL8jbqO3xUVArNd_7Njf4rfZpuL2vps7DjqYOOcVYcoJp1kFT79B27inEL9m0JCQCK5EKSqFwdlUsw5WXeaBEG1y07V7BRmiqiaXeVP_pz-hI9h1Xp7qPtc7M9TWadbxQURTH34vFLsy-X662uBFK3--cH3283_X_4NdcGySQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1770396773</pqid></control><display><type>article</type><title>The origin of fibrin breakdown products and the interpretation of their appearance in the circulation</title><source>PubMed Central</source><creator>Gallimore, M. J. ; Tyler, H. M. ; Shaw, J. T. B.</creator><creatorcontrib>Gallimore, M. J. ; Tyler, H. M. ; Shaw, J. T. B.</creatorcontrib><description>It has been shown that the incubation of human plasma with urokinase at a concentration sufficient to cause rapid lysis of the clots formed on the addition of thrombin does not give rise to the production of measurable concentrations of non-clottable fibrinogen breakdown products. Also, breakdown products could not be detected in the course of experiments in vivo when urokinase was administered to monkeys and only in very low concentrations when a fibrinolytic state was induced by exercise in three healthy human volunteers. In contrast, high concentrations of breakdown products were found after thrombin infusion into monkeys. It is concluded that circulating fibrinogen is not readily broken down into non-clottable products by the fibrinolytic enzymes, and that normal animals and healthy human subjects do not have substantial deposits of fibrin that are available for breakdown during a fibrinolytic episode. The presence of breakdown products in the circulation is therefore likely to be indicative of the fibrinolytic response to an initial coagulation event.</description><identifier>ISSN: 0021-9746</identifier><identifier>EISSN: 1472-4146</identifier><identifier>DOI: 10.1136/jcp.25.3.185</identifier><identifier>PMID: 4622995</identifier><identifier>CODEN: JCPAAK</identifier><language>eng</language><publisher>England: BMJ Publishing Group Ltd and Association of Clinical Pathologists</publisher><subject>Adult ; Animals ; Blood Coagulation ; Fibrin - analysis ; Fibrinogen - analysis ; Fibrinolysis ; Fibrinolytic Agents - pharmacology ; Haplorhini ; Humans ; Macaca ; Male ; Peptides - blood ; Physical Exertion ; Thrombin - pharmacology ; Time Factors</subject><ispartof>Journal of clinical pathology, 1972-03, Vol.25 (3), p.185-190</ispartof><rights>Copyright BMJ Publishing Group LTD Mar 1972</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b476t-9a7d315fff21f594029ac75b738d0a523df96065308dc59a5c980f312bf10cb93</citedby><cites>FETCH-LOGICAL-b476t-9a7d315fff21f594029ac75b738d0a523df96065308dc59a5c980f312bf10cb93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC477259/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC477259/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/4622995$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gallimore, M. J.</creatorcontrib><creatorcontrib>Tyler, H. M.</creatorcontrib><creatorcontrib>Shaw, J. T. B.</creatorcontrib><title>The origin of fibrin breakdown products and the interpretation of their appearance in the circulation</title><title>Journal of clinical pathology</title><addtitle>J Clin Pathol</addtitle><description>It has been shown that the incubation of human plasma with urokinase at a concentration sufficient to cause rapid lysis of the clots formed on the addition of thrombin does not give rise to the production of measurable concentrations of non-clottable fibrinogen breakdown products. Also, breakdown products could not be detected in the course of experiments in vivo when urokinase was administered to monkeys and only in very low concentrations when a fibrinolytic state was induced by exercise in three healthy human volunteers. In contrast, high concentrations of breakdown products were found after thrombin infusion into monkeys. It is concluded that circulating fibrinogen is not readily broken down into non-clottable products by the fibrinolytic enzymes, and that normal animals and healthy human subjects do not have substantial deposits of fibrin that are available for breakdown during a fibrinolytic episode. The presence of breakdown products in the circulation is therefore likely to be indicative of the fibrinolytic response to an initial coagulation event.</description><subject>Adult</subject><subject>Animals</subject><subject>Blood Coagulation</subject><subject>Fibrin - analysis</subject><subject>Fibrinogen - analysis</subject><subject>Fibrinolysis</subject><subject>Fibrinolytic Agents - pharmacology</subject><subject>Haplorhini</subject><subject>Humans</subject><subject>Macaca</subject><subject>Male</subject><subject>Peptides - blood</subject><subject>Physical Exertion</subject><subject>Thrombin - pharmacology</subject><subject>Time Factors</subject><issn>0021-9746</issn><issn>1472-4146</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1972</creationdate><recordtype>article</recordtype><recordid>eNp90cmPFCEUB2BiNGM7evNqUomJXqyWneIwB9MuY9LRy6iJF0JRMENPNZRAufz30ks66sEThPc9eOQHwGMElwgR_nJjpiVmS7JEHbsDFogK3FJE-V2wgBCjVgrK74MHOW8gREQgcgbOKMdYSrYA9urGNjH5ax-a6Brn-1R3fbL6dog_QjOlOMym5EaHoSnV-lBsmpItuvi476mnPjV6mqxOOpgd2Uvjk5nHPXsI7jk9ZvvouJ6DT2_fXK0u2_XHd-9Xr9ZtTwUvrdRiIIg55zByTFKIpTaC9YJ0A9QMk8FJDjkjsBsMk5oZ2UFHEO4dgqaX5BxcHO6d5n5rB2NDSXpUU_JbnX6pqL36uxL8jbqO3xUVArNd_7Njf4rfZpuL2vps7DjqYOOcVYcoJp1kFT79B27inEL9m0JCQCK5EKSqFwdlUsw5WXeaBEG1y07V7BRmiqiaXeVP_pz-hI9h1Xp7qPtc7M9TWadbxQURTH34vFLsy-X662uBFK3--cH3283_X_4NdcGySQ</recordid><startdate>19720301</startdate><enddate>19720301</enddate><creator>Gallimore, M. J.</creator><creator>Tyler, H. M.</creator><creator>Shaw, J. T. B.</creator><general>BMJ Publishing Group Ltd and Association of Clinical Pathologists</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19720301</creationdate><title>The origin of fibrin breakdown products and the interpretation of their appearance in the circulation</title><author>Gallimore, M. J. ; Tyler, H. M. ; Shaw, J. T. B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b476t-9a7d315fff21f594029ac75b738d0a523df96065308dc59a5c980f312bf10cb93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1972</creationdate><topic>Adult</topic><topic>Animals</topic><topic>Blood Coagulation</topic><topic>Fibrin - analysis</topic><topic>Fibrinogen - analysis</topic><topic>Fibrinolysis</topic><topic>Fibrinolytic Agents - pharmacology</topic><topic>Haplorhini</topic><topic>Humans</topic><topic>Macaca</topic><topic>Male</topic><topic>Peptides - blood</topic><topic>Physical Exertion</topic><topic>Thrombin - pharmacology</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gallimore, M. J.</creatorcontrib><creatorcontrib>Tyler, H. M.</creatorcontrib><creatorcontrib>Shaw, J. T. B.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gallimore, M. J.</au><au>Tyler, H. M.</au><au>Shaw, J. T. B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The origin of fibrin breakdown products and the interpretation of their appearance in the circulation</atitle><jtitle>Journal of clinical pathology</jtitle><addtitle>J Clin Pathol</addtitle><date>1972-03-01</date><risdate>1972</risdate><volume>25</volume><issue>3</issue><spage>185</spage><epage>190</epage><pages>185-190</pages><issn>0021-9746</issn><eissn>1472-4146</eissn><coden>JCPAAK</coden><abstract>It has been shown that the incubation of human plasma with urokinase at a concentration sufficient to cause rapid lysis of the clots formed on the addition of thrombin does not give rise to the production of measurable concentrations of non-clottable fibrinogen breakdown products. Also, breakdown products could not be detected in the course of experiments in vivo when urokinase was administered to monkeys and only in very low concentrations when a fibrinolytic state was induced by exercise in three healthy human volunteers. In contrast, high concentrations of breakdown products were found after thrombin infusion into monkeys. It is concluded that circulating fibrinogen is not readily broken down into non-clottable products by the fibrinolytic enzymes, and that normal animals and healthy human subjects do not have substantial deposits of fibrin that are available for breakdown during a fibrinolytic episode. The presence of breakdown products in the circulation is therefore likely to be indicative of the fibrinolytic response to an initial coagulation event.</abstract><cop>England</cop><pub>BMJ Publishing Group Ltd and Association of Clinical Pathologists</pub><pmid>4622995</pmid><doi>10.1136/jcp.25.3.185</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0021-9746
ispartof Journal of clinical pathology, 1972-03, Vol.25 (3), p.185-190
issn 0021-9746
1472-4146
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_477259
source PubMed Central
subjects Adult
Animals
Blood Coagulation
Fibrin - analysis
Fibrinogen - analysis
Fibrinolysis
Fibrinolytic Agents - pharmacology
Haplorhini
Humans
Macaca
Male
Peptides - blood
Physical Exertion
Thrombin - pharmacology
Time Factors
title The origin of fibrin breakdown products and the interpretation of their appearance in the circulation
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T23%3A16%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20origin%20of%20fibrin%20breakdown%20products%20and%20the%20interpretation%20of%20their%20appearance%20in%20the%20circulation&rft.jtitle=Journal%20of%20clinical%20pathology&rft.au=Gallimore,%20M.%20J.&rft.date=1972-03-01&rft.volume=25&rft.issue=3&rft.spage=185&rft.epage=190&rft.pages=185-190&rft.issn=0021-9746&rft.eissn=1472-4146&rft.coden=JCPAAK&rft_id=info:doi/10.1136/jcp.25.3.185&rft_dat=%3Cproquest_pubme%3E81423895%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b476t-9a7d315fff21f594029ac75b738d0a523df96065308dc59a5c980f312bf10cb93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1770396773&rft_id=info:pmid/4622995&rfr_iscdi=true